Abstract: The Wnt/b-catenin signaling pathway has been one of the most common molec- ular targets of cancer treatment, owing to its involvement in the formation and development of many malignant tumors. It is also signi¯cantly involved in tumor immunoregulation, and abnormally activated Wnt/b-catenin signaling is closely linked to the immunosuppressive microenvironment of tumors. Immune checkpoint inhibitors have been widely studied and used for cancer treatment, but using inhibitors targeting programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) results in tumor drug resistance and low patient response rates. Activation of the Wnt/b-catenin pathway inhibits CD8+ T cell in¯ltration into the tumor microenviron- ment, which inhibits anti-tumor immune response and induces immune checkpoint inhibitor resistance. This review focuses on the relationship between the Wnt/b-catenin signaling pathway and immune checkpoints and reviews the research progress on the treatment of malignant tumors utilizing a combination of Wnt/b-catenin and immune checkpoint in- hibitors.

Key words: Wnt/b-catenin signaling pathway, immune checkpoint, immune escape, immunosuppressive microenvironment